Archive · 9 Nov 2025
Syngene Eyes Growth Fueled by Global Trial Wins and Biotech Funding
Syngene, a company that helps other drug companies, is celebrating a major win: their first big contract to help with a late-stage drug test that includes patients in both India and the US.
This is a big step for Syngene as they aim to do more of these important global tests.
While they are dealing with some costs from a new factory in India, which has lowered their current profits a bit, they are also seeing good signs.
Money is starting to flow back into new biotech companies in America, meaning they will likely need Syngene's help more.
Syngene also bought a factory in the US that will start working soon, and they are building up expertise in new kinds of medicines.
Even with a slight dip in profits this past quarter, Syngene is looking forward to future growth.
Syngene has secured its first global Phase 3 clinical trial mandate with a US biotech firm, recruiting patients in both India and the US.
The company is experiencing near-term profitability pressure due to depreciation from its new biologics facility and inventory adjustments.
Syngene anticipates future growth from the recovering venture capital funding in the US biotech sector.
A recently acquired US biologics facility is expected to begin operations in the second half of FY26.
Syngene reported a 37% year-on-year dip in net profit to ₹67 crore for Q2 FY26, despite a 2% rise in revenues to ₹911 crore.
- Who
- Syngene International, led by MD and CEO Peter Bains
- What
- Secured its first global Phase 3 clinical trial mandate and is preparing for growth driven by recovering biotech funding and facility expansions.
- When
- November 9, 2025 (publication date); Q2 FY26 financial results reported.
- Where
- India and US (for clinical trials); Bengaluru (biologics facility); US (acquired Bayview biologics facility).
- Why
- To expand into late-stage global trials, capitalize on renewed venture capital funding in biotech, and leverage new facilities and modalities.
Profitability Pressure
Growth Opportunities
Near-term Financials
Profitability Pressure
Net profit dipped 37% year-on-year to ₹67 crore in Q2 FY26, impacted by depreciation costs from a new biologics facility and inventory adjustments with a large customer.
Growth Opportunities
Revenue rose 2% to ₹911 crore in Q2 FY26, with future growth anticipated from increased utilization of the new biologics facility and recovering venture capital funding in US biotech.
Facility Impact
Profitability Pressure
Depreciation costs from the newly operationalized Bengaluru biologics facility are a current drag on profitability.
Growth Opportunities
The acquired US biologics facility is expected to begin operations in the second half of FY26, contributing to future capacity and revenue generation.
- Net Profit (Q2 FY26)
- ₹67 crore (down 37% YoY)
- Revenues (Q2 FY26)
- ₹911 crore (up 2% YoY)
- First Global Phase 3 Trial
- Secured with a US biotech firm, recruiting patients in India and US
- US Biologics Facility Acquisition
- $36.5 million
- US Biologics Facility Operation Start (Expected)
- Second half of FY26
- Key Growth Drivers
- Late-stage global trials, recovering US biotech VC funding, new modalities (ADCs, peptides)